{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "Cet article r\u00e9sume les r\u00e9cents travaux de recherche sur le risque \u00e9lev\u00e9 de r\u00e9currence, les cancers de la peau multiples et les seconds cancers primitifs chez le nombre croissant de gens ayant eu un cancer de la peau, ceci afin de mieux \u00e9valuer le fardeau des tumeurs malignes apr\u00e8s un cancer de la peau. Recenser et suivre les cas de cancer de la peau, tant les m\u00e9lanomes que les non-m\u00e9lanomes (NM), pr\u00e9sente des difficult\u00e9s. La plupart des autorit\u00e9s ne font pas le suivi syst\u00e9matique des cas de NM. m\u00eame lorsqu\u2019elles le font, elles n\u2019incluent d\u2019habitude que le premier diagnostic. Il y a diff\u00e9rentes r\u00e8gles pour compter les m\u00e9lanomes multiples, et l\u2019on ne tient pas compte des r\u00e9currences pour les deux grands types de cancer de la peau. Si l\u2019on appliquait aux chiffres canadiens sur le cancer les \u00e9clairages apport\u00e9s par les \u00e9tudes r\u00e9centes sur la question, on augmenterait d\u2019environ 26 % les diagnostics d\u00e9clar\u00e9s de N. et de 10 % les diagnostics d\u00e9clar\u00e9s de m\u00e9lanome au Canada. Cette \u00e9valuation plus globale du fardeau des cancers de la peau s\u2019appelle \u00abapproche de l\u2019incidence fond\u00e9e sur le diagnostic \u00bb, par opposition \u00e0 une approche fond\u00e9e sur les patients. Un autre aspect dont on ne tient g\u00e9n\u00e9ralement pas compte lorsqu\u2019on \u00e9value le fardeau des cancers de la peau est le risque de 20 % \u00e0 30 % plus \u00e9lev\u00e9 de second cancer primitif non cutan\u00e9 apr\u00e8s une tumeur primitive de la peau. Recenser et suivre les cas de cancer de la peau, tant les m\u00e9lanomes que les non-m\u00e9lanomes (NM), pr\u00e9sente des difficult\u00e9s. La plupart des autorit\u00e9s ne font pas le suivi syst\u00e9matique des cas de NM. m\u00eame lorsqu\u2019elles le font, elles n\u2019incluent d\u2019habitude que le premier diagnostic. Il y a diff\u00e9rentes r\u00e8gles pour compter les m\u00e9lanomes multiples, et l\u2019on ne tient pas compte des r\u00e9currences pour les deux grands types de cancer de la peau. Si l\u2019on appliquait aux chiffres canadiens sur le cancer les \u00e9clairages apport\u00e9s par les \u00e9tudes r\u00e9centes sur la question, on augmenterait d\u2019environ 26 % les diagnostics d\u00e9clar\u00e9s de N. et de 10 % les diagnostics d\u00e9clar\u00e9s de m\u00e9lanome au Canada. Cette \u00e9valuation plus globale du fardeau des cancers de la peau s\u2019appelle \u00abapproche de l\u2019incidence fond\u00e9e sur le diagnostic \u00bb, par opposition \u00e0 une approche fond\u00e9e sur les patients. Un autre aspect dont on ne tient g\u00e9n\u00e9ralement pas compte lorsqu\u2019on \u00e9value le fardeau des cancers de la peau est le risque de 20 % \u00e0 30 % plus \u00e9lev\u00e9 de second cancer primitif non cutan\u00e9 apr\u00e8s une tumeur primitive de la peau. Pour r\u00e9sumer, les sujets ayant un cancer de la peau pr\u00e9sentent un risque \u00e9lev\u00e9 de r\u00e9currence, de cancers de la peau multiples et de second cancer primitif. Ce fardeau devrait \u00eatre un sujet de pr\u00e9occupation pour le bassin vaste et grandissant des sujets ayant eu un cancer de la peau, ainsi que pour les planificateurs en pr\u00e9vention."
      ]
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "21033542",
  "DateCompleted": {
    "Year": "2010",
    "Month": "12",
    "Day": "10"
  },
  "DateRevised": {
    "Year": "2021",
    "Month": "10",
    "Day": "20"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0008-4263",
      "JournalIssue": {
        "Volume": "101",
        "Issue": "4",
        "PubDate": {
          "Year": "2010",
          "Season": "Jul-Aug"
        }
      },
      "Title": "Canadian journal of public health = Revue canadienne de sante publique",
      "ISOAbbreviation": "Can J Public Health"
    },
    "ArticleTitle": "Burden of malignancy after a primary skin cancer: recurrence, multiple skin cancers and second primary cancers.",
    "Pagination": {
      "StartPage": "I23",
      "EndPage": "I27",
      "MedlinePgn": "I23-7"
    },
    "Abstract": {
      "AbstractText": [
        "The current paper summarizes relevant recent research on the high risk of recurrence, multiple skin cancers and second primary cancers in the growing number of people with a history of skin cancer; the ultimate purpose is to better assess the burden of malignancy following skin cancer. A number of challenges exist in identifying and tracking both melanoma and non-melanoma skin cancer (NMSC) cases. Most jurisdictions do not routinely track NMSC cases and, even if they do, it is customary to only include the first diagnosis. There are variable rules for counting multiple melanoma cancers, and recurrences are not considered for either major type of skin cancer. Applying insights from recent studies of this issue to Canadian cancer statistics would increase reported diagnoses of NMSC by about 26% and melanoma by 10% in this country. This approach to a fuller assessment of the burden of skin cancers has been called a \"diagnosis-based incidence approach\" as compared with a \"patient-based incidence approach\". A further issue that is not usually taken into account when assessing the burden of skin cancers is the 20% to 30% elevated risk of noncutaneous second primary cancers following a primary skin tumour. In summary, individuals with skin cancer are subject to a high risk of recurrence, multiple skin cancers and second primary cancers. This burden should be a special concern in the large and growing pool of individuals with a history of skin cancer, as well as among prevention planners."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "H. Krueger and Associates Inc., Delta, BC. hans@krueger.ca"
          }
        ],
        "LastName": "Krueger",
        "ForeName": "Hans",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Williams",
        "ForeName": "Dan",
        "Initials": "D"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Research Support, Non-U.S. Gov't"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Switzerland",
    "MedlineTA": "Can J Public Health",
    "NlmUniqueID": "0372714",
    "ISSNLinking": "0008-4263"
  },
  "MeshHeadingList": [
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Canada"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Neoplasm Recurrence, Local"
    },
    {
      "QualifierName": [
        "epidemiology",
        "pathology"
      ],
      "DescriptorName": "Neoplasms, Multiple Primary"
    },
    {
      "QualifierName": [
        "epidemiology",
        "pathology"
      ],
      "DescriptorName": "Neoplasms, Second Primary"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Risk"
    },
    {
      "QualifierName": [
        "epidemiology",
        "pathology"
      ],
      "DescriptorName": "Skin Neoplasms"
    }
  ]
}